Icon

TAVALISSE (nda209299)- (EQ 100MG BASE,EQ 150MG BASE)

FOSTAMATINIB DISODIUM RIGEL PHARMS
EQ 100MG BASE,EQ 150MG BASE
Yes No
2032-Jul-27 2023-Apr-17
None None
None No
TAVALISSE is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
0 1 0
Total Other Developers 1
Drugs with Suitability No
EQ 100MG BASE ** ** - - -
EQ 150MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.